S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
The Real Problem With "Made in America" Lithium (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
The Real Problem With "Made in America" Lithium (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
The Real Problem With "Made in America" Lithium (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
The Real Problem With "Made in America" Lithium (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
The Real Problem With "Made in America" Lithium (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
The Real Problem With "Made in America" Lithium (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
The Real Problem With "Made in America" Lithium (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
The Real Problem With "Made in America" Lithium (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Forecast, Price & News

$11.29
+0.09 (+0.80%)
(As of 06/1/2023 ET)
Compare
Today's Range
$10.69
$11.34
50-Day Range
$7.65
$12.16
52-Week Range
$6.88
$22.87
Volume
262,504 shs
Average Volume
174,066 shs
Market Capitalization
$498.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
125.9% Upside
$25.50 Price Target
Short Interest
Bearish
17.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.81mentions of Stoke Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$500,098 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.53) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

601st out of 1,980 stocks

Pharmaceutical Preparations Industry

279th out of 978 stocks


STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
12 Analysts Have This to Say About Stoke Therapeutics
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
H.C. Wainwright Remains a Buy on Stoke Therapeutics (STOK)
See More Headlines

STOK Price History

STOK Company Calendar

Last Earnings
5/04/2023
Today
6/02/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.50
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+125.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-101,070,000.00
Net Margins
-679.83%
Pretax Margin
-679.83%

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$4.84 per share

Miscellaneous

Free Float
38,577,000
Market Cap
$498.91 million
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Edward M. KayeEdward M. Kaye
    Chief Executive Officer & Director
  • Huw M. NashHuw M. Nash
    Chief Operating & Business Officer
  • Stephen J. Tulipano
    Chief Financial Officer
  • Barry S. TichoBarry S. Ticho
    Chief Medical Officer
  • Isabel Aznarez
    Group Vice President-Discovery Research













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2023?

8 Wall Street research analysts have issued 1-year price targets for Stoke Therapeutics' shares. Their STOK share price forecasts range from $12.00 to $35.00. On average, they predict the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 125.9% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2023?

Stoke Therapeutics' stock was trading at $9.23 on January 1st, 2023. Since then, STOK shares have increased by 22.3% and is now trading at $11.29.
View the best growth stocks for 2023 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Thursday, May, 4th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.17. The company earned $5.15 million during the quarter, compared to analyst estimates of $3.57 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 47.86% and a negative net margin of 679.83%.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.94%), Cowen AND Company LLC (7.42%), Baker BROS. Advisors LP (4.79%), FMR LLC (4.45%), BlackRock Inc. (4.18%) and Deutsche Bank AG (1.62%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $11.29.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $498.91 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 102 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -